Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients With Irritable Bowel Syndrome

Background: Little is known regarding the clinical impact of treatment and treatment duration of probiotic VSL#3 on gut and microbiome function in irritable bowel syndrome (IBS). As part of a safety trial, we assessed the effect of VSL#3 treatment duration on abdominal pain, stooling, gut permeabili...

Descripción completa

Detalles Bibliográficos
Autores principales: Boonma, Prapaporn, Shapiro, Jordan M., Hollister, Emily B., Badu, Shyam, Wu, Qinglong, Weidler, Erica M., Abraham, Bincy P., Devaraj, Sridevi, Luna, Ruth Ann, Versalovic, James, Heitkemper, Margaret M., Savidge, Tor C., Shulman, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pain Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915646/
https://www.ncbi.nlm.nih.gov/pubmed/35295488
http://dx.doi.org/10.3389/fpain.2021.691689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915646/
https://www.ncbi.nlm.nih.gov/pubmed/35295488
http://dx.doi.org/10.3389/fpain.2021.691689

Ejemplares similares